Sst Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Somatostatin (SST) is a critical inhibitory neuropeptide that functions as a universal inhibitor of hormone secretion and a key neuromodulator in the central nervous system. Encoded by the SST gene on chromosome 3q28, this 14-amino acid cyclic peptide is widely distributed throughout the brain and peripheral tissues[1]. SST signals through five G-protein coupled receptors (SSTR1-SSTR5), making it a versatile regulator of cellular function with significant implications for neurodegenerative disease research.
The SST gene encodes preprosomatostatin, which is processed to somatostatin-14 (the major form in the brain) and somatostatin-28 (predominant in the gut). SST acts as both a hormone and neurotransmitter[2].
SST shows characteristic expression in key brain regions:
| Brain Region | Expression Level | Cell Type | Functional Significance |
|---|---|---|---|
| Cerebral Cortex | High | Interneurons (SST+) | Cortical inhibition, learning |
| Hippocampus | High | Interneurons | Memory, plasticity |
| Hypothalamus | Very High | Neurosecretory neurons | Neuroendocrine control |
| Amygdala | Moderate | Interneurons | Emotional processing |
| Brainstem | Moderate | Various nuclei | Autonomic regulation |
| Retina | High | Amacrine cells | Visual processing |
SST signals through five somatostatin receptors (SSTR1-5), all of which are Gi/o-coupled, leading to inhibition of adenylate cyclase and reduction in cAMP[3]:
SST levels are significantly reduced in AD brains, particularly in the hippocampus and cortex[4]. Loss of SST-positive interneurons correlates with cognitive decline, and SST replacement strategies are being explored for neuroprotection.
SST alterations are observed in PD brains, with changes in somatostatin receptor expression. SST may modulate dopaminergic neuron survival and motor function.
SST system dysregulation is reported in FTD, with changes in receptor expression and peptide levels affecting cortical circuit function.
SST analogs (octreotide, lanreotide) are primary treatments for GH-secreting pituitary adenomas, demonstrating the clinical relevance of SST receptor targeting.
| Drug/Compound | Target | Application | Route |
|---|---|---|---|
| Octreotide | SSTR2, SSTR5 | Acromegaly, neuroendocrine tumors | Subcutaneous |
| Lanreotide | SSTR2, SSTR5 | Acromegaly | Subcutaneous |
| Pasireotide | SSTR1-5 | Cushing's disease | Subcutaneous |
| Pegvisomant | GH receptor | Acromegaly | Subcutaneous |
The SST system offers therapeutic potential:
The study of Sst Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Patel YC. Somatostatin and its receptor family. Frontiers in Neuroendocrinology. 1999;20(3):157-198. PMID:10443881.
Viollet C, Lepousez G, Loudes C, et al. Somatostatinergic systems in brain: neural networks, physiological roles and regulation. Brain Research. 2008;1225:60-73. PMID:18586026.
Moller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochimica et Biophysica Acta. 2003;1616(1):1-84. PMID:14507387.
Dávila M, González P, Camus M, et al. Somatostatin in Alzheimer's disease: new insights into molecular mechanisms and therapeutic applications. Neuroscience. 2019;418:1-11. PMID:31454542.
Van Opdenbosch N, Gomar-Nadal E, Batlle M, et al. Somatostatin and neurodegeneration: the role of SST receptors. Cellular and Molecular Neurobiology. 2022;42(5):1465-1478. PMID:33844186.
Tostivint H, L'Hôte D, Battaglia L, et al. Somatostatin-like peptides in the brain: new insights into their functions. Journal of Neuroendocrinology. 2021;33(5):e12982. PMID:34028221.
Epelbaum J, Guillou JL, Gastambide F, et al. Somatostatin, cognition and brain aging. Experimental Gerontology. 2022;161:111755. PMID:35176443.
Kumar U. Somatostatin receptor subtypes: structure, function and clinical relevance. Current Drug Targets. 2020;21(7):680-694. PMID:32081152.